US 12,220,437 B2
Oncolytic virus improved in safety and anticancer effect
Taeho Hwang, Yangsan-si (KR); and Mong Cho, Yangsan-si (KR)
Assigned to BIONOXX INC., Seongnam-si (KR)
Filed by BIONOXX INC., Seongnam-si (KR)
Filed on Oct. 23, 2023, as Appl. No. 18/492,535.
Application 18/492,535 is a division of application No. 16/957,511, granted, now 11,857,585, previously published as PCT/KR2018/016874, filed on Dec. 28, 2018.
Claims priority of provisional application 62/611,174, filed on Dec. 28, 2017.
Claims priority of application No. 10-2018-0106841 (KR), filed on Sep. 7, 2018.
Prior Publication US 2024/0100108 A1, Mar. 28, 2024
Int. Cl. A61K 35/768 (2015.01); A61K 9/00 (2006.01); A61K 31/522 (2006.01); A61K 31/708 (2006.01); A61K 38/45 (2006.01); A61P 35/00 (2006.01); C12N 9/12 (2006.01); C12N 15/86 (2006.01)
CPC A61K 35/768 (2013.01) [A61K 9/0019 (2013.01); A61K 31/708 (2013.01); C12N 15/86 (2013.01); C12N 2710/24111 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method for treating a cancer in a subject in need thereof, which comprises
administering (a) a recombinant oncolytic virus comprising a nucleotide sequence encoding a truncated fragment of HSV1-TK (herpes simplex virus thymidine kinase) or a variant thereof, and (b) GCV (ganciclovir) or ACV (acyclovir) to the subject,
wherein the truncated fragment of HSV1-TK is any one of fragments in which 1 to 195 amino acid residues are consecutively deleted from the C-terminus of the amino acid sequence of SEQ ID NO: 1, and
wherein the variant of the truncated fragment of HSV1-TK comprises the amino acid sequence of SEQ I NO: 7 or 8.